Bind Therapeutics (BIND) 0.78 $BIND BIND Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bind Therapeutics (BIND) 0.78 $BIND

BIND Therapeutics Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets
BusinessWire - Tue Jul 26, 4:27PM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced that Pfizer Inc. (NYSE: PFE) prevailed at a Section 363 auction to purchase substantially all of BIND's assets. The winning bid of $40 million, subject to U.S. Bankruptcy Court approval for which a hearing is scheduled to take place on July 27, 2016, was selected as the highest and best bid. NanoCarrier Co., Ltd. has been selected as the back-up bidder. The Company plans to disclose additional terms of its agreement with Pfizer upon Court approval.
PFE: 37.31 (+0.42), BIND: 0.78 (-0.09)

Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics
PR Newswire - Thu Jun 23, 7:20AM CDT
On Wednesday, June 22, 2016, the NASDAQ Composite ended the trading session at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% lower to finish at 17,780.83; and the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Nektar Therapeutics (NASDAQ: NKTR), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and BIND Therapeutics Inc. (NASDAQ: BIND). Learn more about these stocks by accessing their free trade alerts at:
BIND: 0.78 (-0.09), ARLZ: 3.89 (+0.39), INFI: 1.69 (+0.01), NKTR: 17.76 (+0.47)

7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.36 (unch), RTRX: 18.17 (+0.24), AVEO: 0.99 (-0.01), SNSS: 0.70 (+0.05), LGND: 138.53 (+3.65), BIND: 0.78 (-0.09), ACOR: 25.13 (-0.15)

BIND Therapeutics Provides Update on Chapter 11 Proceedings and Announces Agreement with Hercules Technology III, L.P.
BusinessWire - Thu May 19, 7:00AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced an agreement has been reached with its secured lender Hercules Technology III, L.P., an affiliate of Hercules Capital (NYSE: HTCG), for the use of cash collateral through July 8, 2016 subject to certain agreed upon terms and conditions. As part of the agreement negotiated under BIND's voluntary chapter 11 filing, the Company has agreed, among other things, to pay-down $4 million in principal on the existing principal loan balance of approximately $12.4 million.
BIND: 0.78 (-0.09)

Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS(R) to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics
BusinessWire - Tue May 10, 7:00AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced the publication of detailed methods for its hydrophobic ion pairing (HIP) approach that can be applied to a wide range of ionizable molecules, greatly increasing the diversity of payloads that can be encapsulated in ACCURINS(R). Previous data demonstrated the potential of ACCURINS(R) to deliver the aurora B kinase inhibitor AZD2811 to tumor sites and in this publication, researchers from BIND Therapeutics and AstraZeneca describe the preparation of nanoparticles encapsulating AZD2811 in detail and characterize their pharmacokinetics, tolerability and mechanisms of tumor growth inhibition in preclinical models. The data are published in the May 10, 2016 issue of the Journal of Controlled Release.
BIND: 0.78 (-0.09)

Bind Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 6:23AM CDT
CAMBRIDGE, Mass. (AP) _ Bind Therapeutics Inc. (BIND) on Monday reported a loss of $12.7 million in its first quarter.
BIND: 0.78 (-0.09)

BIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Mon May 09, 6:00AM CDT
BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS(R), today reported financial results for the first quarter ended March 31, 2016 and provided a business update.
BIND: 0.78 (-0.09)

Is a Surprise Coming for BIND Therapeutics (BIND) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 7:36AM CDT
BIND Therapeutics (BIND) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory.
BIND: 0.78 (-0.09)

BIND Therapeutics Announces Collaboration with Affilogic to Provide BIND with Access to Targeting Ligands that are Key Modulators of Anti-tumor Immunity
BusinessWire - Thu May 05, 7:00AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced a research collaboration with Affilogic, a privately held biotechnology company developing affinity proteins called Nanofitins(R) that selectively bind and interact with identified targets. Under terms of the collaboration, BIND will utilize Nanofitins(R) as targeting ligand components for ACCURINS(R) designed to bind immuno-oncology targets. Upon achievement of proof-of-concept, BIND anticipates expanding the collaboration to develop ACCURINS(R) that incorporate unique combinations of immuno-oncology targeting ligands and new classes of payloads, including oligonucleotides and molecularly targeted therapies.
BIND: 0.78 (-0.09)

What's in the Cards for Synta (SNTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 4:58AM CDT
Synta Pharmaceuticals (SNTA), which is expected to report first-quarter 2016 results on May 5, had posted a positive surprise of 21.52% last quarter.
IPXL: 31.15 (-0.27), SNTA: 0.34 (+0.07), JAZZ: 150.53 (-0.44), BIND: 0.78 (-0.09)

What's in Store for Horizon (HZNP) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 9:40AM CDT
Horizon Pharma (HZNP), which is set to report first-quarter 2016 results on May 9, recorded a negative earnings surprise of 20% last quarter.
IPXL: 31.15 (-0.27), JAZZ: 150.53 (-0.44), HZNP: 18.89 (-0.40), BIND: 0.78 (-0.09)

BIND Therapeutics to Report First Quarter 2016 Financial Results on May 9, 2016
BusinessWire - Tue May 03, 3:01PM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced it will host a conference call and audio webcast on May 9, 2016, at 8:30 a.m. ET to report first quarter 2016 financial results and provide a business update.
BIND: 0.78 (-0.09)

Merck (MRK) Q1 Earnings: Can the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:12AM CDT
Will Merck (MRK) maintain its impressive track record and deliver a positive earnings surprise this quarter as well?
MRK: 58.66 (unch), BIND: 0.78 (-0.09), CHMA: 2.70 (+0.05), FOLD: 6.71 (-0.01)

Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 138.53 (+3.65), SPPI: 7.05 (+0.18), BIND: 0.78 (-0.09), FOLD: 6.71 (-0.01)

DaVita (DVA) Likely to Top Q1 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 7:08AM CDT
We expect DaVita HealthCare Partners Inc. (DVA) to beat expectations when it reports first-quarter 2016 results on May 4, after the market closes.
ACET: 25.46 (-0.25), BDX: 176.78 (+0.78), DVA: 77.00 (-0.54), BIND: 0.78 (-0.09)

BIND Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Protection Proceeding
BusinessWire - Mon May 02, 5:00AM CDT
BIND Therapeutics, Inc. (NASDAQ:BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS(R), today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
BIND: 0.78 (-0.09)

PeptiDream Announces Research Collaboration with BIND Therapeutics
BusinessWire - Wed Apr 06, 9:33AM CDT
PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream"(TOKYO:4587) announced today that it has entered into a research collaboration with US-based BIND Therapeutics (NASDAQ: BIND). PeptiDream intends to use its Peptide Discovery Platform System (PDPS) technology to identify macrocyclic peptides that can be utilized as biologically active targeting ligands with BIND's proprietary Accurin nanoparticles (ACCURINS(R)). BIND has selected targeting ligands of interest to accelerate the Company's innovative medicines strategy focused on products that elicit tumor cell death and modulate the tumor microenvironment to maximize clinical benefit for patients.
BIND: 0.78 (-0.09)

BIND Therapeutics Reports Phase 2 Data from iNSITE 1 and iNSITE 2 Trials with BIND-014 and Provides Strategic Update
BusinessWire - Wed Apr 06, 8:25AM CDT
--Company to implement restructuring plan in line with previously announced shift in R&D strategy to leverage the platform to develop innovative medicines and initiate a review of financial and strategic alternatives
BIND: 0.78 (-0.09)

Biotech Sector Report Analyst; Expecting FDA Results
ACCESSWIRE - Mon Mar 28, 7:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / MannKind Corporation (NASDAQ: MNKD), Keryx Biopharmaceuticals. (NASDAQ: KERX), Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), and BIND Therapeutics Inc. (NASDAQ: BIND) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
PGNX: 5.84 (-0.01), BIND: 0.78 (-0.09), MNKD: 1.02 (+0.03), KERX: 4.72 (-2.64)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 255

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 69

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 136

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 131

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 148

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
Fold Health's AI: Revolutionizing Patient Care Dynamics

Updated Category News Views 140

AI's Role in Healthcare: From Insight to Action Healthcare's got a resource issue, plain and simple. It's like trying to fill a bathtub with a hole in it—clinicians are swamped, burnout is high, and patients aren't getting the attention they need. Enter Fold Health's AI operating layer, launched with the ambition to realign the equation. Not Just Another Tech Buzzword...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 63

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 165

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 120

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Insights from OncoHost in Lung Cancer Treatment Strategy

Updated Category News Views 149

New Advances in Understanding Lung Cancer Treatment Resistance Recent findings from OncoHost shed light on the mechanisms behind resistance to immunotherapy in patients battling lung cancer. The study presents vital insights aimed at improving therapeutic strategies through advanced plasma proteomics analysis. Insights from Advanced Plasma Proteomics OncoHost, a...

Continue Reading
Understanding Eldorado Gold's Current Market Position and P/E

Updated Category News Views 167

Analyzing Eldorado Gold Inc's Current Market Situation At present, Eldorado Gold Inc. (NYSE: EGO) shares trade at a price of $27.34, reflecting a decrease of 5.85% in the current session. This decline comes after a slight drop of 1.19% over the past month. Despite this short-term volatility, when looking over a longer timeline, the stock shows impressive growth, having...

Continue Reading
Truecaller Achieves Remarkable Growth with 450 Million Users

Updated Category News Views 218

Truecaller Reaches 450 Million Monthly Active Users Truecaller, the renowned platform dedicated to verifying contacts and blocking unwanted communications, has reached a significant milestone, surpassing 450 million active users. This achievement marks another step in its impressive growth trajectory over the last year, with around 50 million new users added in just ten...

Continue Reading
Shell plc's Recent Share Buybacks: Key Insights Revealed

Updated Category News Views 377

Overview of Shell plc's Share Buyback Activities Shell plc has recently initiated significant share buyback activities as part of its ongoing strategy to enhance shareholder value. This move demonstrates the company's commitment to investing back into itself and optimizing capital allocation. The buybacks reflect Shell's strong financial position and positive outlook on...

Continue Reading
Wyndham Hotels Investigation: Uncovering Potential $50 Million Loss

Updated Category News Views 324

Investigation into Wyndham Hotels Sparks Concern Recent findings from internal records of Wyndham Hotels & Resorts have revealed alarming information suggesting that the Royalton Letter of Credit (LOC) was fully funded but not released. This situation raises troubling questions about potential securities and franchise-law violations involving multiple parties....

Continue Reading